US-based AI-powered biotech Gensaic, Inc. announced the signing of a licensing and discovery cooperation agreement with Denmark-based Novo Nordisk A/S (NYSE: NVO). The collaboration, combining Novo’s deep therapeutic knowledge and drug development experience with Gensaic’s novel protein design technology, is designed to discover tissue-targeting ligands and develop new therapeutic candidates to treat cardiometabolic disease via undisclosed targets.
Financial Terms
Under the agreement, Gensaic is eligible to receive up to USD 354 million in upfront payments, development, and commercial milestones per target, plus tiered royalties. Novo will also reimburse research and development costs and participate in a future financing round. An executive of Novo will join Gensaic’s board as a non-voting observer member.
Collaboration Details
Gensaic will be responsible for discovering novel protein ligands, while Novo Nordisk retains the rights to leverage these for further development. The collaboration includes Novo Nordisk’s license and option right to advance multiple therapeutic programs through research, development, and commercialization.-Fineline Info & Tech
Leave a Reply